Stemline Therapeutics, Inc. (NASDAQ:STML) has been given a $34.00 target price by research analysts at HC Wainwright in a research note issued on Wednesday. The firm currently has a “buy” rating on the biopharmaceutical company’s stock. HC Wainwright’s price target suggests a potential upside of 297.66% from the stock’s current price.

STML has been the topic of a number of other research reports. Cowen and Company reaffirmed a “buy” rating on shares of Stemline Therapeutics in a research report on Friday, May 12th. Jefferies Group LLC reaffirmed a “buy” rating and set a $16.00 price objective on shares of Stemline Therapeutics in a research report on Thursday, May 25th. Zacks Investment Research downgraded Stemline Therapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday, July 18th. Wedbush raised their price objective on Stemline Therapeutics from $33.00 to $40.00 and gave the company an “outperform” rating in a research report on Thursday, May 11th. Finally, BidaskClub raised Stemline Therapeutics from a “hold” rating to a “buy” rating in a research report on Wednesday, July 19th. Two analysts have rated the stock with a sell rating and seven have assigned a buy rating to the company’s stock. Stemline Therapeutics has a consensus rating of “Buy” and a consensus price target of $29.17.

Stemline Therapeutics (NASDAQ STML) opened at 8.55 on Wednesday. The stock’s market cap is $199.86 million. Stemline Therapeutics has a 52-week low of $5.50 and a 52-week high of $14.60. The stock has a 50 day moving average price of $9.34 and a 200 day moving average price of $8.61.

Stemline Therapeutics (NASDAQ:STML) last posted its quarterly earnings results on Wednesday, May 10th. The biopharmaceutical company reported ($0.67) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.45) by $0.22. Stemline Therapeutics had a negative return on equity of 60.51% and a negative net margin of 3,864.20%. The firm had revenue of $0.30 million for the quarter, compared to the consensus estimate of $0.30 million. Analysts expect that Stemline Therapeutics will post ($2.24) EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “Stemline Therapeutics, Inc. (NASDAQ:STML) PT Set at $34.00 by HC Wainwright” was reported by Daily Political and is owned by of Daily Political. If you are accessing this report on another publication, it was copied illegally and republished in violation of U.S. & international copyright and trademark law. The original version of this report can be read at https://www.dailypolitical.com/2017/08/09/stemline-therapeutics-inc-nasdaqstml-pt-set-at-34-00-by-hc-wainwright.html.

A number of large investors have recently modified their holdings of the stock. AXA bought a new stake in shares of Stemline Therapeutics during the first quarter worth $3,712,000. Renaissance Technologies LLC increased its stake in shares of Stemline Therapeutics by 7.9% in the fourth quarter. Renaissance Technologies LLC now owns 65,500 shares of the biopharmaceutical company’s stock valued at $701,000 after buying an additional 4,800 shares in the last quarter. Eventide Asset Management LLC increased its stake in shares of Stemline Therapeutics by 27.6% in the first quarter. Eventide Asset Management LLC now owns 1,086,400 shares of the biopharmaceutical company’s stock valued at $9,289,000 after buying an additional 235,000 shares in the last quarter. State Street Corp increased its stake in shares of Stemline Therapeutics by 9.2% in the fourth quarter. State Street Corp now owns 251,804 shares of the biopharmaceutical company’s stock valued at $2,694,000 after buying an additional 21,296 shares in the last quarter. Finally, Bailard Inc. increased its stake in shares of Stemline Therapeutics by 12.1% in the first quarter. Bailard Inc. now owns 138,785 shares of the biopharmaceutical company’s stock valued at $1,187,000 after buying an additional 15,000 shares in the last quarter. 53.99% of the stock is currently owned by institutional investors.

About Stemline Therapeutics

Stemline Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing oncology therapeutics. The Company is developing approximately three clinical stage product candidates, including SL-401, SL-701 and SL-801. SL-401 is a targeted therapy directed to the interleukin-3 receptor (IL-3R) (CD123), present on a range of hematologic cancers.

Analyst Recommendations for Stemline Therapeutics (NASDAQ:STML)

Receive News & Ratings for Stemline Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stemline Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.